Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effects of extensive Weight loss on Insulin resistance and Lipid-kinetics in people with obesity and fatty liver Disease
2023-506300-12-00Phase 4Completed
- Sponsor
- Central Denmark Region
- Start
- Aug 2023
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 4, open-label trial of semaglutide in obesity and metabolic dysfunction-associated steatotic liver disease (MASLD) (2 arms), sponsored by Central Denmark Region. Primary endpoint: Change in VLDL-triglyceride kinetics. Started Aug 2023; status: completed.
02
Drugs
03
Conditions
obesitymetabolic dysfunction-associated steatotic liver disease (MASLD)
Beyond the preview
Go deeper on 2023-506300-12-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506300-12-00.